Ondine Biomedical reveals its technology can tackle a range of the worst bacteria
The company's photodisinfection technology was shown to be effective against so-called ESKAPE pathogens
Company
Ondine Biomedical Inc
LON:OBI
Ondine Biomedical Inc. is a Canadian life sciences company pioneering light-activated therapies designed to prevent and treat infections, including those caused by drug-resistant pathogens. The company's patented photodisinfection platform technology targets harmful microbes without contributing to antimicrobial resistance, offering a powerful new approach to infection prevention.
73 stories · page 4 of 4
Ondine Biomedical hails result from phase II photodisinfection study
The company's method involves applying a solution to each nostril that is activated by laser light
Ondine Biomedical highlights paper showing effectiveness of aPDT against SARS-CoV-2
"Nasal photodisinfection provides healthcare systems with a simple, rapid, cost-effective treatment to protect against COVID-19"
Ondine Biomedical completes recruitment for phase 2 nasal pathogen trial
The single-centre open-label study is being carried out at HCA Healthcare's Memorial Health University Medical Center in Savannah, Georgia
Ondine's photodisinfection technology ‘rapidly and substantially suppresses’ Covid replication
The latest study, carried out by the Clínica Universidad de Navarra, Spain, confirms earlier work carried out in Canada
Ondine Biomedical sets solid foundations for progress
The update was provided alongside full-year results
Ondine says study confirms photodisinfection is effective against SARS-CoV-2
The non-toxic nature makes it possible to provide safe, fast, and efficient nasal photodisinfection of COVID-19 patients, according to principal investigator Professor Luis Arnaut
Ondine Biomedical treats first patient in phase II FDA study
Researchers will evaluate the technology's ability to prevent surgical site infections, which are estimated to affect 300,000 people every year
Anti-microbial resistance study puts spotlight on technologies that reduce dependence on antibiotics
Companies working on reducing dependence on antibiotics include Ondine Biomedical, while others working on anti-microbial resistance include Destiny Pharma
Ondine Biomedical makes senior sales and marketing hire
Charles Young is joining the group as its vice-president of sales and marketing in North America
Ondine Biomedical teams up with leading Spanish university for Covid trial of photodisinfection technology
The firm's Steriwave broad-spectrum antimicrobial has been successfully used in Canadian hospitals for more than ten years. Scientists hope to show it is effective in battling Covid
Ondine Biomedical appoints health expert to advise on use of its technology against COVID-19
The company is a pioneer of photodisinfection, a non-antibiotic antimicrobial approach that rapidly destroys pathogens
London flooded with a December rush of AIM IPOs
The run-up to Christmas is supposed to be a quiet period for new listings. Not so this time around. In all, we are expecting 11 flotations between now and the end of 2021